RA-9
CAS No. 919091-63-7
RA-9 ( —— )
产品货号. M22045 CAS No. 919091-63-7
RA-9 是一种有效的、选择性的蛋白酶体相关去泛素化酶 (DUB) 抑制剂,具有良好的毒性和抗癌活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥365 | 有现货 |
|
| 10MG | ¥616 | 有现货 |
|
| 25MG | ¥1077 | 有现货 |
|
| 50MG | ¥1596 | 有现货 |
|
| 100MG | ¥2495 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称RA-9
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述RA-9 是一种有效的、选择性的蛋白酶体相关去泛素化酶 (DUB) 抑制剂,具有良好的毒性和抗癌活性。
-
产品描述RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines.The characterization of RA-9 as a small-molecule inhibitor of proteasome-associated DUBs.?Treatment with RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors.?Loss of cell viability following RA-9 exposure is associated with an unfolded protein response as mechanism to compensate for unsustainable levels of proteotoxic stress.?In vivo treatment with RA-9 retards tumor growth, increases overall survival, and was well tolerated by the host.
-
体外实验Cell Viability Assay Cell Line:Cisplatin-sensitive ovarian cancer cell lines TOV-21G and ES-2, Cisplatin-resistant ovarian cancer cell lines HEY and OVCAR-3, primary ovarian cancer cellsConcentration:10, 20, 30 μM Incubation Time:48 hours Result:Compromised the viability of ovarian cancer cells in a dose-dependent fashion.Cell Cycle Analysis Cell Line:ES-2 cells Concentration:1.25, 5 μM Incubation Time:18 hours Result:Resulted in a dose-dependent increase in the fraction of ES-2 cells in the G2-M cell cycle phase.Western Blot Analysis Cell Line:ES-2, SKOV-3 and TOV-21G ovarian cancer cells Concentration:5 μM Incubation Time:0-24 h Result:Caused a time-dependent increase in the steady levels of the early ER-stress marker GRP-78, as well as the late ER-stress markers IRE1-α and Ero1L-α.
-
体内实验Animal Model:Six-week-old female immunodeficient (NCr nu/nu) mice Dosage:5 mg/kg Administration:I.p; one-day on, two-days off Result:Significant reduction in tumor burden at day 12.
-
同义词——
-
通路Apoptosis
-
靶点Apoptosis
-
受体Apoptosis|deubiquitinating enzymes (DUBs)
-
研究领域——
-
适应症——
化学信息
-
CAS Number919091-63-7
-
分子量365.34
-
分子式C19H15N3O5
-
纯度>98% (HPLC)
-
溶解度DMSO:4 mg/mL (10.95 mM; ultrasonic and warming and heat to 80°C)
-
SMILES[O-][N+](=O)c1ccc(\C=C2/CNC\C(=C/c3ccc(cc3)[N+]([O-])=O)C2=O)cc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Coughlin K , Anchoori R , Iizuka Y , et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20(12):3174-86.
产品手册
关联产品
-
CSRM617 hydrochlorid...
CSRM617 hydrochloride 是转录因子 ONECUT2 (OC2,雄激素受体 AR 的主要调节剂) 的选择性小分子抑制剂,在 SPR 测定中 Kd 为 7.43 uM,直接与 OC2-HOX 结构域结合。CSRM617 hydrochloride 通过切割 Caspase-3 和 PARP 诱导细胞凋亡 (apoptosis)。CSRM617 hydrochloride 在小鼠的前列腺癌模型中耐受性良好。
-
AAPK-25
AAPK-25 是一种有效的选择性 Aurora/PLK 双重抑制剂,通过生物标志物组蛋白 H3Ser10 的磷酸化,导致有丝分裂延迟和细胞中期停滞,随后导致细胞凋亡激增。
-
Mitoguazone
Mitoguazone(Methylglyoxal-bis(guanylhydrazone)) 是一种具有有效抗肿瘤活性的合成多羰基衍生物。Mitoguazone 是一种可透过血脑屏障的竞争性的 S-腺苷-蛋氨酸脱羧酶 (S-adenosyl-methionine decarboxylase) 抑制剂,可破坏多胺的生物合成。Mitoguazone 诱导细胞凋亡 (apoptosis),可抑制 HIV DNA 整合到单核细胞和巨噬细胞中的细胞 DNA 中。Mitoguazone 具可用于急性白血病,霍奇金淋巴瘤和非霍奇金淋巴瘤的研究。
021-51111890
购物车()
sales@molnova.cn

